FI113007B - Menetelmä ja koostumus siittiöiden hedelmöityskyvyn lisäämiseksi - Google Patents

Menetelmä ja koostumus siittiöiden hedelmöityskyvyn lisäämiseksi Download PDF

Info

Publication number: FI113007B
Authority: FI; Finland
Prior art keywords: sperm; thymosin; fertility; antibody; peptide
Prior art date: 1992-11-17

Application number

FI952381A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI952381L (fi

FI952381A0 (fi

Inventor

Rajesh K Naz

Allan L Goldstein

Original Assignee

Einstein Coll Med

Univ George Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-17

Filing date

1995-05-16

Publication date

2004-02-27

1995-05-16 Application filed by Einstein Coll Med, Univ George Washington filed Critical Einstein Coll Med

1995-05-16 Publication of FI952381A0 publication Critical patent/FI952381A0/fi

1995-07-11 Publication of FI952381L publication Critical patent/FI952381L/fi

2004-02-27 Application granted granted Critical

2004-02-27 Publication of FI113007B publication Critical patent/FI113007B/fi

Links

238000000034 method Methods 0.000 title claims description 38
230000001965 increasing effect Effects 0.000 title claims description 21
239000000203 mixture Substances 0.000 title claims description 11
230000004720 fertilization Effects 0.000 title description 4
108010046075 Thymosin Proteins 0.000 claims description 43
230000035558 fertility Effects 0.000 claims description 32
102000007501 Thymosin Human genes 0.000 claims description 23
239000000725 suspension Substances 0.000 claims description 18
210000000582 semen Anatomy 0.000 claims description 16
238000000338 in vitro Methods 0.000 claims description 13
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 13
108090000765 processed proteins & peptides Proteins 0.000 claims description 12
208000021267 infertility disease Diseases 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 9
230000002708 enhancing effect Effects 0.000 claims description 9
239000012634 fragment Substances 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 5
101800001530 Thymosin alpha Proteins 0.000 claims description 3
235000013399 edible fruits Nutrition 0.000 claims description 3
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
125000002091 cationic group Chemical group 0.000 claims 1
239000000411 inducer Substances 0.000 claims 1
210000004027 cell Anatomy 0.000 description 36
230000000694 effects Effects 0.000 description 23
238000011534 incubation Methods 0.000 description 20
238000011282 treatment Methods 0.000 description 16
235000013601 eggs Nutrition 0.000 description 15
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
239000002953 phosphate buffered saline Substances 0.000 description 14
210000000287 oocyte Anatomy 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 10
210000004681 ovum Anatomy 0.000 description 10
230000030120 acrosome reaction Effects 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
108090000107 Acrosin Proteins 0.000 description 6
102100026041 Acrosin Human genes 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000002775 capsule Substances 0.000 description 5
239000000284 extract Substances 0.000 description 5
208000000509 infertility Diseases 0.000 description 5
230000036512 infertility Effects 0.000 description 5
231100000535 infertility Toxicity 0.000 description 5
230000035699 permeability Effects 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000002611 ovarian Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
210000001541 thymus gland Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000699800 Cricetinae Species 0.000 description 3
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
102000002322 Egg Proteins Human genes 0.000 description 2
108010000912 Egg Proteins Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000007466 Male Infertility Diseases 0.000 description 2
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000007978 cacodylate buffer Substances 0.000 description 2
HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
239000002555 ionophore Substances 0.000 description 2
230000000236 ionophoric effect Effects 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000019100 sperm motility Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LBBAKTMYSIFTBS-UHFFFAOYSA-N 3-[(4-aminophenyl)diazenyl]benzene-1,2-diamine Chemical compound C1=CC(N)=CC=C1N=NC1=CC=CC(N)=C1N LBBAKTMYSIFTBS-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000720330 Homo sapiens Acrosin Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
101000689397 Phasmahyla jandaia Phylloseptin-J4 Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010042573 Superovulation Diseases 0.000 description 1
101710145873 Thymosin beta Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000003710 calcium ionophore Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006059 cover glass Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
230000004886 head movement Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000009027 insemination Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000006993 memory improvement Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000012466 permeate Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000009612 semen analysis Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000002087 whitening effect Effects 0.000 description 1
239000008096 xylene Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Public Health (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Pregnancy & Childbirth (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

FI952381A 1992-11-17 1995-05-16 Menetelmä ja koostumus siittiöiden hedelmöityskyvyn lisäämiseksi FI113007B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US97785192A	1992-11-17	1992-11-17
US97785192		1992-11-17
US9310620		1993-11-05
PCT/US1993/010620 WO1994012144A2 (en)	1992-11-17	1993-11-05	Treatment of infertility and enhancement of fertilization capacity in mammalian males

Publications (3)

Publication Number	Publication Date
FI952381A0 FI952381A0 (fi)	1995-05-16
FI952381L FI952381L (fi)	1995-07-11
FI113007B true FI113007B (fi)	2004-02-27

Family

ID=25525581

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI952381A FI113007B (fi)	1992-11-17	1995-05-16	Menetelmä ja koostumus siittiöiden hedelmöityskyvyn lisäämiseksi

Country Status (16)

Country	Link
US (1)	US5585234A (xx)
EP (1)	EP0668876B1 (xx)
JP (1)	JP3989531B2 (xx)
KR (1)	KR100298858B1 (xx)
CN (1)	CN1153589C (xx)
AU (1)	AU679952B2 (xx)
CA (1)	CA2148689C (xx)
DE (1)	DE69330884T2 (xx)
DK (1)	DK0668876T3 (xx)
ES (1)	ES2164696T3 (xx)
FI (1)	FI113007B (xx)
NO (1)	NO320944B1 (xx)
PH (1)	PH31119A (xx)
TW (1)	TW234692B (xx)
WO (1)	WO1994012144A2 (xx)
ZA (1)	ZA938599B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE29811046U1 (de) *	1998-06-23	1998-09-10	Chang, Kwei-Tang, Panchiao, Taipeh	Topfdeckel des Doppelfunktionsfiltertyps
US20030135876A1 (en) *	2002-01-16	2003-07-17	Larry Mobraaten	Maintenance of genetic lines using cryopreserved sperm
IT201900016319A1 (it) *	2019-09-13	2021-03-13	Luigina Romani	Timosina alfa 1 per l’uso nel trattamento dell’infertilità maschile da esposizione a metalli pesanti.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4612365A (en) *	1980-03-25	1986-09-16	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften	Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
EP0056594B1 (de) *	1981-01-14	1984-09-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Thymosin-alpha-1-Fragmente enthaltende Arzneimittel mit immunregulierender Wirkung und Thymosin-alpha-1-Fragmente
US4444757A (en) *	1981-11-16	1984-04-24	Research Corporation	Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4950590A (en) *	1986-01-13	1990-08-21	Board Of Governors Of Wayne State University	Method and kit for assay for measurement of serum thymosin alpha1

1992
- 1992-11-18 TW TW081109236A patent/TW234692B/zh active
1993
- 1993-09-27 CN CNB931193478A patent/CN1153589C/zh not_active Expired - Fee Related
- 1993-11-05 KR KR1019950701678A patent/KR100298858B1/ko not_active IP Right Cessation
- 1993-11-05 EP EP94901266A patent/EP0668876B1/en not_active Expired - Lifetime
- 1993-11-05 ES ES94901266T patent/ES2164696T3/es not_active Expired - Lifetime
- 1993-11-05 DE DE69330884T patent/DE69330884T2/de not_active Expired - Fee Related
- 1993-11-05 JP JP51314894A patent/JP3989531B2/ja not_active Expired - Fee Related
- 1993-11-05 AU AU55921/94A patent/AU679952B2/en not_active Ceased
- 1993-11-05 WO PCT/US1993/010620 patent/WO1994012144A2/en active IP Right Grant
- 1993-11-05 DK DK94901266T patent/DK0668876T3/da active
- 1993-11-05 CA CA002148689A patent/CA2148689C/en not_active Expired - Fee Related
- 1993-11-16 PH PH47268A patent/PH31119A/en unknown
- 1993-11-17 ZA ZA938599A patent/ZA938599B/xx unknown
1994
- 1994-04-15 US US08/227,990 patent/US5585234A/en not_active Expired - Lifetime
1995
- 1995-05-16 FI FI952381A patent/FI113007B/fi active
- 1995-05-16 NO NO19951932A patent/NO320944B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2164696T3 (es)	2002-03-01
CA2148689C (en)	1998-12-29
TW234692B (xx)	1994-11-21
WO1994012144A3 (en)	1994-07-21
FI952381L (fi)	1995-07-11
WO1994012144A2 (en)	1994-06-09
EP0668876B1 (en)	2001-10-04
NO320944B1 (no)	2006-02-20
KR950703984A (ko)	1995-11-17
CN1153589C (zh)	2004-06-16
DK0668876T3 (da)	2001-12-03
DE69330884T2 (de)	2002-06-06
CN1112444A (zh)	1995-11-29
CA2148689A1 (en)	1994-06-09
EP0668876A1 (en)	1995-08-30
NO951932D0 (no)	1995-05-16
JP3989531B2 (ja)	2007-10-10
PH31119A (en)	1998-02-23
JPH08503705A (ja)	1996-04-23
AU5592194A (en)	1994-06-22
US5585234A (en)	1996-12-17
KR100298858B1 (ko)	2001-11-14
NO951932L (no)	1995-05-16
ZA938599B (en)	1994-06-28
AU679952B2 (en)	1997-07-17
FI952381A0 (fi)	1995-05-16
DE69330884D1 (de)	2001-11-08

Publication	Publication Date	Title
Omer-Ali et al.	1986	A major role for carbohydrate epitopes preferentially recognized by chronically infected mice in the determination of Schistosoma mansoni schistosomulum surface antigenicity.
PT501882E (pt)	2000-12-29	Processo de imunoneutralizacao anti-lhrm de animais domesticos machos nao castrados e peptido para esse fim
US5871748A (en)	1999-02-16	Method of treating viral diseases in animals
Unanue	1970	Thymus dependency of the immune response to hemocyanin: an evaluation of the role of macrophages in thymectomized mice
RU2187333C2 (ru)	2002-08-20	Вакцина для защиты свиней от репродуктивного и респираторного синдрома и способ защиты свиней
Levy et al.	2005	Survey of zona pellucida antigens for immunocontraception of cats
RU2573422C2 (ru)	2016-01-20	Пептид, полученный из человеческого лактоферрина, для применения в качестве агента, маскирующего антиген
Andresen et al.	1989	Echinostoma caproni in mice: shedding of antigens from the surface of an intestinal trematode
Acosta et al.	1983	Anti-striated muscle antibody activity produced by Trypanosoma cruzi
Harrison et al.	1986	Passive protection against Taenia saginata infection in cattle by a mouse monoclonal antibody reactive with the surface of the invasive oncosphere
FI113007B (fi)	2004-02-27	Menetelmä ja koostumus siittiöiden hedelmöityskyvyn lisäämiseksi
RU2745720C2 (ru)	2021-03-31	Иммуногенная композиция lhrh и ее применение у свиней
Kaul et al.	2001	Immunocontraceptive potential of recombinant bonnet monkey (Macaca radiata) zona pellucida glycoprotein-C expressed in Escherichia coli and its corresponding synthetic peptide
CN108567973A (zh)	2018-09-25	一种胎盘样硫酸软骨素a免疫组合物及应用
IE914128A1 (en)	1992-06-03	Gestational agents for controlling cell proliferation
Naz et al.	1992	Thymosin alpha-1 enhances the fertilizing capacity of human sperm cell: implication in diagnosis and treatment of male infertility
Ijaz et al.	1990	Neuroimmunomodulation of in vivo anti-rotavirus humoral immune response
Al-Mufarrej et al.	1997	Effects of royal jelly on the humoral antibody response and blood chemistry of chickens
HUT52788A (en)	1990-08-28	Process for production of biologically active peptides and antigene medical compositions containing these peptides as active substance
RU2283666C2 (ru)	2006-09-20	Средство для активации восстановления структуры и функции поврежденных тканей и органов
Leung	1983	Antiserum to rat visceral yolk sac endoderm induced abnormal embryonic development
Haneji et al.	1987	The antibody from an infertile woman that induces sperm agglutination interacts with rat testicular cells and sperm
Eski et al.	2019	INVESTIGATION OF THE IMMUNOCASTRATION EFFICACY AND LONGEVITY OF A SINGLE DOSE GNRH VACCINE IN YOUNG MALE RATS
YOSHIKAWA et al.	1978	Experimentally-induced agammaglobulinemia in Japanese quails
RU2287345C2 (ru)	2006-11-20	Средство для стимуляции выработки фактора viii свертывания крови